Dan Eramian oversees communications and media strategy and execution at BVGH. He has over 20 years of experience in developing communication and investor programs in the biotechnology industry. Dan was the first Vice President of Communications for the Biotechnology Innovation Organization (BIO) in Washington DC. He worked closely with BVGH Board member and past BIO CEO and President, Carl Feldbaum to make BIO one of the most persuasive industry voices on Capitol Hill as well as promoting understanding and growth of the industry to the public and financial communities. Dan is a co-founder of Opus Biotech Communications, a communications firm aimed at emerging life sciences companies. Previously Dan was Senior Vice President of Communications and Investor Relations at three Seattle based biotechnology companies: KPI Therapeutics, Kineta, Inc. and Cell Therapeutics. Dan has served as Director of Public Affairs for the U.S. Department of Justice and the spokesman for the Attorney General of the United States. He was also Assistant Administrator for Public Affairs at the U.S. Small Business Administration which included its technology development programs. In addition Dan was Chief of Staff in the Massachusetts State Senate and was previously Executive Editor of Suburban World Newspapers also in Massachusetts. He holds a BA in English Literature UMass-Amherst and MPA from Suffolk University.